Renovorx Inc (RNXT) Stock Price, Quote & News

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 650 284 4433

Fax: 650 397 4433

Website: renovorx.com

Address:

2570 West El Camino Real, Suite 320, Mountain View, United States

iAccess_Alpha Dec. 5 at 2:28 PM

$RNXT will present next week at iAccess Alpha’s Virtual Best Ideas Winter Conference. December 9, 2025 | 12:30 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 14, 2025 💊 $RNXT 💵 Entry: $0.8250 ✅ Ext: $0.9562 💰 P/L: +15.90% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 17, 2025 💊 $RNXT 💵 Entry: $0.8176 ✅ Ext: $0.9492 💰 P/L: +16.10% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Wolfietrader Dec. 4 at 9:13 PM

$RNXT maybe. Just maybe..

0 · Reply

Rnxtsavior Dec. 4 at 10:41 AM

$RNXT Under a dollar warning notice should be coming soon. That should drop sp another..30-.40 All heading to the reverse split. Wiping out all current shareholders. The sheeny man's plan.

0 · Reply

joemama718 Dec. 2 at 12:29 AM

$RNXT i saw a news piece on this company on nbc in nyc the gentleman (pancreatic cancer)was given 6 months to live and that was like 5 or 7 years ago he was treated with TAMP...this got me looking at rnxt as an investment but from what i see there is little interest in this stock, "long term" performance is abysmal (not too concerned...they will burn cash until approval), but why such a bad track record (stock price) when seemingly the future is very bright. I'd consider this a spec long term hold. What am i missing? TIA

3 · Reply

iAccess_Alpha Dec. 1 at 3:54 PM

$RNXT will present at iAccess Alpha’s Virtual Best Ideas Winter Conference. December 9–10, 2025 Full conference details: https://www.accessnewswire.com/newsroom/en/business-and-professional-services/iaccess-alphas-virtual-best-ideas-winter-investment-conference-d-1112775 #microcap #smallcap #investing

0 · Reply

Mehle Dec. 1 at 10:28 AM

$RNXT looks like we come back over 1 Dollar

1 · Reply

IUsedToWorkAtBYND Nov. 28 at 2:14 PM

$RNXT This stock isn't going to a damn thing of significance until one of their products actually gets approved for treatment outside of "another" study. This stock is one to forget about for like a year at least. 2027 is their real target. If this stock is one of your bulk stocks in your portfolio and you are stressing over it, get out now because you are an idiot.

0 · Reply

Rnxtsavior Nov. 28 at 1:43 PM

$RNXT going up on very low volume.. Something bad is about to happen... reverse split? Offering...again?

1 · Reply

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th

Nov 19, 2025, 8:30 AM EST - 16 days ago

RenovoRx CEO Shaun Bagai to Present at the Alliance Global Partners Emerging AgBiotech/Bio-Solutions Virtual Showcase on November 20th

Nov 13, 2025, 4:05 PM EST - 22 days ago

RenovoRx Reports Third Quarter 2025 Financial Results, Including Approximately $900,000 in Year-to-Date Revenue, and Provides Business Update

Nov 6, 2025, 8:30 AM EST - 4 weeks ago

RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

Nov 4, 2025, 8:30 AM EST - 4 weeks ago

RenovoRx CEO Shaun Bagai to Participate at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum on November 20th

Oct 27, 2025, 8:30 AM EDT - 5 weeks ago

RenovoRx to Host Third Quarter 2025 Financial Results and Business Highlights Conference Call on November 13th at 4:30 p.m. ET

Oct 9, 2025, 8:30 AM EDT - 2 months ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Sep 25, 2025, 8:30 AM EDT - 2 months ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 11, 2025, 8:30 AM EDT - 3 months ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Aug 20, 2025, 8:30 AM EDT - 3 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 14, 2025, 4:05 PM EDT - 4 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 6, 2025, 8:30 AM EDT - 4 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Jul 28, 2025, 8:30 AM EDT - 4 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 14, 2025, 8:30 AM EDT - 5 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

May 15, 2025, 9:07 PM EDT - 7 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 4:05 PM EDT - 7 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 14, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 6, 2025, 8:30 AM EDT - 7 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 1, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Apr 29, 2025, 8:30 AM EDT - 7 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 16, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 4, 2025, 8:30 AM EDT - 8 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 1, 2025, 8:30 AM EDT - 8 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Mar 28, 2025, 8:00 AM EDT - 9 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 26, 2025, 8:00 AM EDT - 9 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 20, 2025, 8:00 AM EDT - 9 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 19, 2025, 8:00 AM EDT - 9 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Feb 26, 2025, 8:00 AM EST - 10 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 13, 2025, 8:00 AM EST - 10 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 11, 2025, 7:00 AM EST - 10 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 10 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 4:05 PM EST - 10 months ago

RenovoRx Announces Proposed Public Offering

Feb 5, 2025, 2:14 AM EST - 10 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Jan 27, 2025, 8:00 AM EST - 11 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 8, 2025, 8:00 AM EST - 11 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Dec 30, 2024, 8:00 AM EST - 1 year ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 10, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders

May 21, 2024, 9:00 AM EDT - 1 year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

Apr 18, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

iAccess_Alpha Dec. 5 at 2:28 PM

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 14, 2025 💊 $RNXT 💵 Entry: $0.8250 ✅ Ext: $0.9562 💰 P/L: +15.90% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

SPYmyQQQ Dec. 4 at 9:21 PM

🎯 Target Hit 🏁 📨 From Nov 17, 2025 💊 $RNXT 💵 Entry: $0.8176 ✅ Ext: $0.9492 💰 P/L: +16.10% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

Wolfietrader Dec. 4 at 9:13 PM

$RNXT maybe. Just maybe..

0 · Reply

Rnxtsavior Dec. 4 at 10:41 AM

$RNXT Under a dollar warning notice should be coming soon. That should drop sp another..30-.40 All heading to the reverse split. Wiping out all current shareholders. The sheeny man's plan.

0 · Reply

joemama718 Dec. 2 at 12:29 AM

3 · Reply

iAccess_Alpha Dec. 1 at 3:54 PM

0 · Reply

Mehle Dec. 1 at 10:28 AM

$RNXT looks like we come back over 1 Dollar

1 · Reply

IUsedToWorkAtBYND Nov. 28 at 2:14 PM

0 · Reply

Rnxtsavior Nov. 28 at 1:43 PM

$RNXT going up on very low volume.. Something bad is about to happen... reverse split? Offering...again?

1 · Reply

Wolfietrader Nov. 26 at 8:37 PM

$RNXT just couldn’t hold $.91 today.

1 · Reply

iAccess_Alpha Nov. 26 at 2:13 PM

$RNXT will present at iAccess Alpha’s Virtual Best Ideas Winter Conference. December 9, 2025 | 12:30 PM ET Access the webcast here: https://www.webcaster5.com/Webcast/Page/3148/53256 #microcap #smallcap #investing

1 · Reply

Wolfietrader Nov. 25 at 9:22 PM

$RNXT a little volume, a little increase, a little hope

0 · Reply

outlawinvestor1 Nov. 25 at 12:44 AM

$RNXT cmo buy.

1 · Reply

brandonscience Nov. 24 at 11:34 PM

$RNXT how are you making sense of CMO buys? Weird to think he doesn't have MNPI.

1 · Reply

CunningStunt69 Nov. 24 at 5:21 PM

$RNXT haven’t seen insider buys since the drop. Last quarter Bagai bought 8-10 days after earnings in the $.90S.

3 · Reply

JarvisFlow Nov. 24 at 2:56 PM

Ascendiant Capital has adjusted their stance on RenovoRx ( $RNXT ), setting the rating to Buy with a target price of 12 → 12.5.

1 · Reply

builderup Nov. 24 at 1:19 PM

$PDSB $IFRX $AMPG $RNXT $BEAT Is it safe to come out. We think it’s time. 👀👀👀. Weekly watchlist.

0 · Reply

IUsedToWorkAtBYND Nov. 21 at 7:38 PM

$RNXT This stock doesn't ever do anything after the post bell, so by it's basically done for the week in about 30 min.

0 · Reply

IUsedToWorkAtBYND Nov. 21 at 4:17 PM

$RNXT I will personally ensure this stock moves today...aiming to like $.83-$.85 range.

1 · Reply

IUsedToWorkAtBYND Nov. 21 at 4:16 PM

$RNXT Full penetration into this stock - feel it!

0 · Reply

IUsedToWorkAtBYND Nov. 21 at 4:16 PM

$RNXT No reverse split happening anytime soon...

0 · Reply

Market Cap	30.98M
Revenue (ttm)	40,000.00
Net Income (ttm)	-8.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-22,025.00%
Debt to Equity Ratio	0.00

Volume	116,000
Avg Vol	448,430
Day's Range	N/A - N/A
Shares Out	36.65M
Stochastic %K	95%
Beta	1.30
Analysts	Strong Sell
Price Target	$5.62